Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Progressing tumors in man and mouse are often infiltrated by dendritic cells (DCs). Deficient antitumor immunity could be related to a lack of tumor-associated antigen (TAA) presentation by tumor-infiltrating DCs (TIDCs) or to a functional defect of TIDCs. Here we investigated the phenotype and function of TIDCs in transplantable and transgenic mouse tumor models. Although TIDCs could encompass various known DC subsets, most had an immature phenotype. We observed that TIDCs were able to present TAA in the context of major histocompatibility complex class I but that they were refractory to stimulation with the combination of lipopolysaccharide, interferon gamma, and anti-CD40 antibody. We could revert TIDC paralysis, however, by in vitro or in vivo stimulation with the combination of a CpG immunostimulatory sequence and an anti-interleukin 10 receptor (IL-10R) antibody. CpG or anti-IL-10R alone were inactive in TIDCs, whereas CpG triggered activation in normal DCs. In particular, CpG plus anti-IL-10R enhanced the TAA-specific immune response and triggered de novo IL-12 production. Subsequently, CpG plus anti-IL-10R treatment showed robust antitumor therapeutic activity exceeding by far that of CpG alone, and elicited antitumor immune memory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The therapeutic effect resulting from enhanced tumor-infiltrating DCs and macrophage infiltrate switching from M2 to M1 consequently produce increased IL-12 and tumor necrosis factor (TNF) (76).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intratumor injections of TLR9 ligand CpG and anti-IL10R antibody are able to reinforce antitumor efficacy in C26 and B16 animal models.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [76]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336 · cited 2×
“Although the main function of dendritic cells (DCs) * is probably to orchestrate a defense against pathogens, DCs are also well equipped to initiate antitumor responses (1).”
BackgroundA Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 1×
“We tested different combinations of substances with the aim of relieving tumor-mediated inhibition and simultaneously mediating DC activation, including combinations of the TLR-9 ligand CpG 1668 (21) and an anti–IL-10R blocking antibody (15).”
MethodMouse and human dendritic cell subtypes
Shortman, K., & Liu, Y.-J. (2002) · Nature Reviews Immunology · doi:10.1038/nri746 · Cited by 2,291 · cited 4×
“In contrast, TIDCs from X/myc hepatocarcinoma were representative of distinct subsets of mouse DCs (19).”
BackgroundResultInfluentialKadowaki, N., Ho, S., Antonenko, S., de Waal Malefyt, R., Kastelein, R. A., Bazan, F., & Liu, Y.-J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.863 · Cited by 1,964 · cited 2×
“Furthermore, it will be of important to test whether our observations also apply to human tumor-infiltrating DCs. Interestingly, a population of plasmacytoid DC precursors has recently been described in human ovarian cancer (27) and these cells, in normal individuals, express TLR9 and respond to selected CpGs (28).”
BackgroundDhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C., & Bhardwaj, N. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.233 · Cited by 1,359 · cited 1×
“Indeed, it was recently reported that immature DC injection would induce antigen-specific T cell unresponsiveness in man (22).”
BackgroundMayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Martin Kast, W., Deleo, A. B., et al. (1995) · Nature Medicine · doi:10.1038/nm1295-1297 · Cited by 1,074
Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology
Asselin-Paturel, C., Boonstra, A., Dalod, M., Durand, I., Yessaad, N., Dezutter-Dambuyant, C., Vicari, A., O'Garra, A., Biron, C., Brière, F., et al. (2001) · Nature Immunology · doi:10.1038/ni736 · Cited by 1,022 · cited 1×
“On the other hand, TIDCs isolated from liver hepatocarcinoma were more diverse, including CD11b and CD11b DCs as well as cells expressing CD8 an/or B220, the latter marker being ascribed to mouse type I IFN-producing cells (19, 20).”
BackgroundSelf-citationZou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Wei, S., Krzysiek, R., Durand-Gasselin, I., Gordon, A., et al. (2001) · Nature Medicine · doi:10.1038/nm1201-1339 · Cited by 653 · cited 1×
“Interestingly, a population of plasmacytoid DC precursors has recently been described in human ovarian cancer (27) and these cells, in normal individuals, express TLR9 and respond to selected CpGs (28).”
BackgroundBell, D., Chomarat, P., Broyles, D., Netto, G., Harb, G. M., Lebecque, S., Valladeau, J., Davoust, J., Palucka, K. A., & Banchereau, J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1417 · Cited by 544
Paglia, P., Chiodoni, C., Rodolfo, M., & Colombo, M. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.317 · Cited by 542
Self-citation
Cited by
Items 301–351 of 351
Dendritic Cells: From Inducers of Specific T-Cell Responses to Promoters of Angiogenesis
Coukos, G., & Benencia, F. (2009) · Springer eBooks · doi:10.1007/978-0-387-88611-4_16 · Cited by 1
“Interestingly, it has been recently shown that the endothelial cell-produced anti-angiogenic cytokine vascular endothelial growth inhibitor also induces DC maturation ( Tian et al. 2007 ).”
BackgroundInnate Immunity-Based Immunotherapy of Cancer
Maruyama, K., Ishii, H., Tai, S., Cheng, J., Satoh, T., Karaki, S., Akimoto, S., & Yamaguchi, K. D. (2012) · InTech eBooks · doi:10.5772/29382 · Cited by 1
“…with monoclonal antibody therapy (Buhtoiarov et al., 2006; Daftarian et al., 2004; Davila et al., 2003; Dercamp et al., 2005; Guiducci et al., 2005; Vicari et al., 2002; Wooldridge et al., 1997), cytokines, chemokines and related factors (Chaudhry et al., 2006; Ishii et al., 2003; Merad et al.,…”
Effects of Traditional Chinese Medicine on DCs Under Tumor Microenvironment
Zeng, Z., Xu, X., & Chen, D. (2015) · SpringerBriefs in biochemistry and molecular biology · doi:10.1007/978-94-017-7405-5_5 · Cited by 1
Dendritic Cell Maturation Versus Polarization in Tumor Escape
Lipscomb, M. W., Storkus, W. J., & Wesa, A. K. (2009) · Springer eBooks · doi:10.1007/978-0-387-88611-4_18 · Cited by 1
“In this light, the results of recent combinational therapies using surgical debulking, DC-activating drugs and/or Treg antagonists (Vicari et al. 2002; Danna et al. 2004; Piconese et al. 2008) are intriguing and may provide clues for the development of translational approaches to mitigate TME-induced DC defects for op…”
BackgroundThe Challenging Triad: Microbiota, Immune System and Anticancer Drugs
Arsene, A. L., Drăgoi, C. M., Nicolae, A. C., Popa, D. E., Burcea-Dragomiroiu, G. T. A., Dumitrescu, I.-B., Timnea, O. C., & Udeanu, D. I. (2016) · InTech eBooks · doi:10.5772/65731 · Cited by 1
Interleukin-1 Superfamily and Cancer
Yuzhalin, A. E., & Kutikhin, A. G. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801121-8.00002-6 · Cited by 2
Alberca, R. W., Gomes, E., & Russo, M. (2021) · Vaccines · doi:10.3390/vaccines9070743 · Cited by 1
Cancer therapy, immunotherapy, photothermal therapy
Liddle, G. M., Wei, J., & Hartmann, J. X. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823033-6.00028-4 · Cited by 1
Cytokine Regulation of Immune Tolerance to Tumors
Li, M. O., & Flavell, R. A. (2007) · Elsevier eBooks · doi:10.1016/b978-012372551-6/50068-7 · Cited by 1
The Links between Inflammation and Cancer
Balkwill, F. R., Charles, K. A., & Mantovani, A. (2007) · Wiley eBooks · doi:10.1002/9780470025079.chap220 · Cited by 1
Coukos, G., & Conejo-Garcia, J. R. (2006) · Humana Press eBooks · doi:10.1385/1-59745-011-1:285 · Cited by 2
External stimuli-responsive nanomedicine for cancer immunotherapy
Niu, L., Jang, E., Chin, A. L., & Tong, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822425-0.00026-9 · Cited by 1
Function and regulation of interleukin-10 in breast cancerPreprint
Research, T. A. O., & Al-Ameri, S. A. A.-E. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/me4a5 · Cited by 2
Interleukin-10 in the Control of Tumor Immunity and Autoimmunity.
Wilke, C. M. (2011) · Deep Blue (University of Michigan)
Stewart, C. A., & Trinchieri, G. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7219-4_4
Self-citationpDC: From Plasmacytoid Dendritic Cell Precursorsto Professional Type 1 Interferon‐producing Cells
Liu, Y., Kanzler, H., Wang, Y., Wang, Y., Gilliet, M. F., Cao, W., & Ito, T. (2006) · Wiley eBooks · doi:10.1002/9783527619696.ch13
Immunomodulatory role of flagellin in antigen-presenting cells
Vicente-Suarez, I. (2007) · Digital Commons - University of South Florida (University of South Florida)
Hurwitz, A. A. (2007) · Defense Technical Information Center (DTIC) · doi:10.21236/ada475839
Modulação da resposta imune durante o desenvolvimento de carcinoma espinocelular
Belai, E. B. (2011) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.25.2011.tde-18012012-143731 · Cited by 1
Artificial Antigen‐Presenting Cells: Large Multivalent Immunogens
Mescher, M. F., & Curtsinger, J. (2012) · Wiley eBooks · doi:10.1002/9781118345313.ch19
de Moraes, C. J. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2013.tde-10062014-111732
Mumm, J. B., Emmerich, J., & Oft, M. (2012) · OncoImmunology · doi:10.4161/onci.21423
Collective action of hematopoietic cell subsets mediates anti-IL10R1 and CpG tumor immunity
Chou, M.-Y., Austin, C. D., & Kim, J. M. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1175-3
“Since NK cell depletion impairs anti-IL-10R1- and CpG-induced growth inhibition of C26 cells [9], the requirement of NK cells was tested in B16F10 melanoma.”
BackgroundResultInfluentialTHE REGULATION OF DENRITIC CELL FUNCTION IN AUTOIMMUNE PRONE AND WILD TYPE MICE
Flores, R. R. (2005) · D-Scholarship@Pitt (University of Pittsburgh)
Human Dendritic Cells in Cancer
Lizee, G. A., & Gilliet, M. F. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9914-6_8
Gautheron, A. (2015) · theses.fr (ABES) · doi:10.70675/1b60a990z1015z4f47z8c2fz84a6b408d4f1
der Abteilung, A., Endres, S., & München, L.-M.-U. (2009)
Characterization of a Novel Dendritic Cell Population
Mikhailova, A. (2012) · TSpace (University of Toronto)
Molecular Mechanisms of Tumor Dendritic Cell Dysfunction in Cancer
Tang, M. (2016) · TSpace (University of Toronto)
Immunomodulation with Adjuvants and Cytokines
Kim, D. W., & Diab, A. K. (2018) · Wiley eBooks · doi:10.1002/9781118684535.ch9
Semiglazova, Т. Y., Бриш, Н. А., Galunova, T. Y., Бернацкий, А. С., & Семиглазов, В. В. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-10-128-133
Etude des voies de recrutement des cellules dendritiques dans une tumeur solide
Boulet, D. (2017) · theses.fr (ABES) · doi:10.70675/e4dd9c54zb11fz423ezaddfz0c7f6af1af14
Cancer immunotherapy targeting T cell costimulatory molecules
Pardee, A. D. (2010) · D-Scholarship@Pitt (University of Pittsburgh)
Immunotherapy With Magentorheologic Fluids
Murphy, W. J., & Evrensel, C. A. (2011)
Using Natural Adjuvants to Stimulate Anti-Tumour Immune Responses
Kuhn, S. P. (2012) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17011490
Interleukin-10 Superfamily and Cancer
Yuzhalin, A. E., & Kutikhin, A. G. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801121-8.00006-3
Role of Monocyte-Derived Dendritic Cells (MoDCs) in Tumor Immune Response
Pourahmad, R., & Rezaei, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00749-0_20
Interleukin-10 (IL-10): Biology, Immune Regulation, and Cancer
Fujii, S., & Lotze, M. T. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-455-1_9
Dendritic Cells and Cancer: Development, Dysfunction and Therapeutic Targets
Watkins, S. K., & Hurwitz, A. A. (2013) · Springer eBooks · doi:10.1007/978-94-007-6217-6_18
Impact of Concurrent Antibiotic & Corticosteroid Use on Efficacy of Immune Checkpoint Inhibitors
Tran, D. (2023) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 2
Węgierek‐Ciura, K., Szczygieł, A., Rudawska, A., Mierzejewska, J., Rossowska, J., Szermer-Olearnik, B., Świtalska, M., Goszczyński, T. M., & Pajtasz‐Piasecka, E. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1773836
“…to block IL-10 activity have been developed, e.g. by directly promoting the activation of intratumoral CD8 + cells (3, 4) or intratumoral application of a lentiviral vector encoding IL-10-silencing short hairpin RNA (shRNA) (5, 6), as well as by blocking IL-10R to enhance myeloid cell function (7).”
Daillère, R. (2015) · theses.fr (ABES) · doi:10.70675/8c6f6318z9ebcz4bbaza1cazfae4f3595d77
Loverre, A. (2024) · theses.fr (ABES) · doi:10.70675/79e19555z0982z4d48zb235z1e77245236cf · Cited by 1
Breast Cancer Milieu Maneuvers Cancer-Associated Macrophages to Synergize Neoplastic Repertoires
Lin, H.-J., Liu, Y., Langevin, B., & Lin, J. (2026) · Cancers · doi:10.3390/cancers18101596
“Accordingly, dual therapy using CpG-ODN and anti-IL-10R favors M1 macrophages and inhibits tumor growth [153,154].”
Transcriptional Regulation of Dendritic Cells in the Tumor Microenvironment
Jiang, A., Stagliano, K. E., Cuss, S. M., Triplett, A., Fu, C., & Hurwitz, A. A. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8056-4_9
“[73], [74].”
Metadata
- Authors
- Vicari, A. P., Chiodoni, C., Vaure, C., Aït-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., O'Garra, A., Trinchieri, G., & Caux, C.
- Affiliations
- 1Schering-Plough Laboratory for Immunological Research, 69571 Dardilly, France
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Inserm (FR)
- 4DNAX Research Institute, Palo Alto, CA 94304
- ORCID
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2002-08-19
- Volume
- 196
- Issue
- 4
- Pages
- 541-549
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2196048
- OpenAlex
- W2156592930
- Cited by
- 343
- References
- 35
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 10 · 2021: 8 · 2020: 8 · 2019: 14 · 2018: 7 · 2017: 19 · 2016: 12 · 2015: 17 · 2014: 21 · 2013: 21 · 2012: 21
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor-infiltrating dendritic cells, MHC class I, DC maturation, IL-12, antitumor immunity, antitumor immune memory, transplantable tumors
- MeSH terms
- Adjuvants, Immunologic, Animals, Antibodies, Monoclonal, Dendritic Cells, Female, Immunity, Active, Immunity, Innate, Immunologic Memory, Interferon-gamma, Killer Cells, Natural, Lipopolysaccharides, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Oligodeoxyribonucleotides, Tumor Cells, Cultured, Antigens, Tumor-Associated, Carbohydrate, Mice, SCID, Receptors, Interleukin, CD8-Positive T-Lymphocytes, CpG Islands, CD40 Antigens, Mice, Receptors, Interleukin-10
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.